analysis for NCT00412984 [clinicaltrials_resource:NCT00412984/analysis/625900fca6e36ebb021b947ad1354421]
analysis for NCT00412984 [clinicaltrials_resource:NCT00412984/analysis/625900fca6e36ebb021b947ad1354421]
Bio2RDF identifier
NCT00412984/analysis/625900fca6e36ebb021b947ad1354421
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... 5900fca6e36ebb021b947ad1354421
ci lower limit [clinicaltrials_vocabulary:ci-lower-limit]
6.800000071525574e-1
ci n sides [clinicaltrials_vocabulary:ci-n-sides]
ci percent [clinicaltrials_vocabulary:ci-percent]
ci upper limit [clinicaltrials_vocabulary:ci-upper-limit]
estimate desc [clinicaltrials_vocabulary:estimate-desc]
apixaban / warfarin
method [clinicaltrials_vocabulary:method]
Cox Proportional Hazard Model
non inferiority [clinicaltrials_vocabulary:non-inferiority]
p value [clinicaltrials_vocabulary:p-value]
p value desc [clinicaltrials_vocabulary:p-value-desc]
nominal two-sided p-value was associated with a test of H0: RR=1 vs H1: RR ≠ 1
param type [clinicaltrials_vocabulary:param-type]
Hazard Ratio (HR)
param value [clinicaltrials_vocabulary:param-value]
7.099999785423279e-1
identifier
clinicaltrials_resource:NCT00412984/analysis/625900fca6e36ebb021b947ad1354421
title
analysis for NCT00412984
@en
type
label
analysis for NCT00412984 [clin ...... 900fca6e36ebb021b947ad1354421]
@en